TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03730870

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics report
Description: Intervention is the performance of a pharmacogenomics laboratory-developed test (LDT) performed by high-throughput sequencing of 38 genes involved in drug pharmacokinetics or pharmacodynamics. The clinician reviews the report results for each subject.
Study: NCT01677676

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1
Description: IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1
Description: IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1-Adjuvant
Description: IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1-Adjuvant
Description: IM injection
Study: NCT02689544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention with static stretching
Description: Members of static stretching group performed three sets of 30 second self hamstring stretch (IT) of both lower limbs, with 30 seconds of rest between sets, totaling 3 minute intervention so.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention with Dynamic Stretching
Description: Each subject contracting antagonist muscle (quadriceps) to the target muscle (hamstring), performing dynamic movements of hip flexion with the knee extended, repeated every 1 second. They amounted to 3 of 30 repetitions completing approximately three minutes of dynamic stretching for each lower.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control group volunteers no received intervention
Study: NCT00255606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given in 3- or 4- week courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given in 3- or 4- week courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given in 3- or 4- week courses
Study: NCT00255606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given in 3- or 4- week courses
Study: NCT01209117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 WBM Capsule
Description: 200 mg GSK2248761 WBM capsule (reference) 2 X100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 WBM Tablet Formulation 1
Description: GSK2248761 WBM Tablet 200mg manufacturing process 1
Study: NCT03556189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Case management
Description: Case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
Study: NCT03552146

Intervention type: DRUG
Intervention: Propofol
Description: Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
Study: NCT03559257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT01209117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 WBM Tablet Formulation 2
Description: GSK2248761 WBM Tablet 200mg manufacturing process 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 WBM Tablet Formulation 3
Description: GSK2248761 WBM Tablet 200mg manufacturing process 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 WBM Tablet
Description: GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4
Study: NCT03670550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossur Rebound ACL Brace
Description: ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy. The intervention (brace) will be applied only to the surgical limb.
Study: NCT04554329

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bandage contact lens
Description: bandage contact lens

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bandage contact lens
Description: bandage contact lens
Study: NCT02352428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Cancer Screening Training
Description: Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
Study: NCT02758106

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vest Airway Clearance System Model 105
Description: HFCWO for 15 minutes then sputum suction.
Study: NCT01408030

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: 0.9%, 0.1 ml spray in each nostril bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 1% solution in saline, 0.1 ml spray in each nostril bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol
Description: 0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 10% solution in saline, 0.1 ml spray in each nostril bid
Study: NCT02758106

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo intervention
Description: CCPT for 15 minutes then sputum suction.
Study: NCT01572844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Carbon Dioxide (FCO2) Laser
Description: At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
Study: NCT03795688

Intervention type: OTHER
Intervention: Pregnancy
Description: Peripartum transition from pregnant to postpartum state
Study: NCT01438853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNX-832
Description: Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg
Study: NCT02658357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Implant
Study: NCT01438853

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous dose of saline control
Study: NCT01518010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play game
Description: Participants engage in non-game activity (establish baseline) 7 \* 1 hr weekly; play single-player game 7 \* 1 hr weekly; play multi-player game 7 \* 1 hr weekly.
Study: NCT03280290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood
Description: assessment pre-donation of hematopoietic stem cells (blood sample)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood
Description: assessment pre-donation of hematopoietic stem cells (blood sample)
Study: NCT04078061

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MABA
Description: Adaptive, modular, behavioral intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EIBI
Description: Early Intensive Behavioral Intervention
Study: NCT04252157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Kinesiotape will be applied to the group. During the orbicularis oris muscle, I tape will be applied around the lip with a mechanical correction technique with 50-75% tension. I tape will be applied just below the Hyoid with a 50-75% tension mechanical correlation technique.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plesebo Taping
Description: An approximately 5 cm I tape will be applied to the group without applying any tension to the temporomandibular attachment for placebo taping.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: no kinesio or tape will be applied
Study: NCT02233556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Taking 20mg(2 capsules) of memantine, followed by Event related potential assessments as below:~1. Mismatch negativity(MMN)~2. P50
Study: NCT00666705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 300 milligrams(mg) every 12 hours Days 6-11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
Study: NCT03259568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive TMS
Description: 1-10 Hertz rTMS will be administered

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive TMS
Description: 1-10 Hertz rTMS will be administered
Study: NCT05393661

Intervention type: OTHER
Intervention: inpatient physical therapy poststroke
Description: routine care
Study: NCT03078283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fiber food type
Description: In 3 successive experiments, usual diet will be supplemented with snack foods containing fiber of plant, fruit or grain origin.
Study: NCT00534287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem
Description: Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem, moxifloxacin
Description: Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
Study: NCT01778335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy/thrombolysis
Description: Endovascular mechanical thrombectomy or thrombolysis
Study: NCT04599894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 37.5mg Pregabalin + 75mg Pregabalin
Description: 37.5mg pregabalin preoperatively + 75mg pregabalin postoperatively

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 75mg Pregabalin
Description: 75mg pregabalin postoperatively
Study: NCT01389154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung biopsy using Always On EM Tip Tracked Device
Description: Patients screened by CT to have a subsegmental, less than 3.0 centimeter lung lesion will be assigned to outpatient bronchoscopy. The patient will have a chest CT with the Always on Patient vPad. Access to the lesion will be achieved using Electromagnetic Tip Tracked devices. Once accessed the operator will use the Electromagnetic Tip Tracked devices or standard devices to obtain a biopsy sample to then be to pathology for diagnosis and reporting. Once completed the patient will be moved to recovery and discharged. If the biopsy is negative the patient will be advised by the pulmonologist about other interventions, watchful waiting, or no further treatment. If the biopsy is positive, the patient will be referred to their physician for further treatment.
Study: NCT04971759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Levobupivacaine 5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Levobupivacaine 5% + 1 µg/kg dexmedetomidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Levobupivacaine 5% + 1µg/kg fentanyl
Study: NCT03080441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pressure stockings
Description: pressure stockings worn during dialysis throughout treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: administered Midodrine before each dialysis treatment during treatment period based on PI's judgement. Including consideration of blood pressure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pressure stockings and midodrine
Description: combination of Midodrine and pressure stocking before each dialysis treatment throughout treatment period
Study: NCT03212612

Intervention type: DIAGNOSTIC_TEST
Intervention: samples obtained by laparoscopy or punch biopsy for analysis by ELISA
Description: Endometrial samples(1-2 gram) will be separated from each women during proliferative phase(days 5-15) by laparoscopy or punch biopsy and washed several times with 0.9% sterile saline solution to remove any blood from the tissues. The tissue samples will homogenized by tissue homogenizer at 40,000rpm. The supernatant extracts will be collected in Ependorf tubes and frozen at -80°C till analysis by ELISA
Study: NCT01026792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01364207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeinated Coffee
Description: Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeinated Coffee
Description: Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated Coffee
Description: Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
Study: NCT02400840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac MRI
Description: Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time
Study: NCT01364207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated Coffee
Description: Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
Study: NCT02919501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (IV)
Description: 17 mg, solution for infusion, administered, over 2 hours as single dose
Study: NCT03649373

Intervention type: PROCEDURE
Intervention: Noergaard technique
Description: The patient is placed standing in an upright position in front of the rail on a hospital bed. Legs should be stretched with a wide well balanced stance. The patient is then instructed to bend forwards, resting the forehead on the back of the non-affected forearm, which is put on the rail. The affected arm should now be relaxed and stretched, hanging straight down toward the floor. The patient is then instructed to attempt to relax and make pendular and circular motions with the affected arm hanging down. Successful reduction occurs when sufficient muscle relaxation allows the humeral head to reposition to its natural position in the glenoid fossa. Often the patient will experience a popping sensation when the shoulder is reduced.
Study: NCT02919501

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (IV)
Description: Saline: isotonic sodium chloride, administered, over 2 hours as single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vortioxetine (tablet)
Description: 10 mg, tablets, oral administration once daily for 15 days (open labelled)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (tablet)
Description: 10 mg, tablets, oral administration once daily for 15 days (open labelled)
Study: NCT01165554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] Flutemetamol
Description: Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.
Study: NCT02400840

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiac MRI
Description: Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadobenic acid intravenous injection 0.2 ml/kg
Description: gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gadobenic acid intravenous injection 0.2 ml/kg
Description: gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment
Study: NCT00324428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: 1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: 1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
Study: NCT00629746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Xomed Nerve Integrity Monitor (NIM)
Description: patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system~1. The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor~2. A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.~3. The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.~4. The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen.
Study: NCT04361604

Intervention type: BIOLOGICAL
Intervention: Biological collection (patients co infected HIV Sras-CoV-2)
Description: Biological sampling (blood,saliva, tear urine, stool, respiratory tract, semen only for 20 patients, or other samples if indicated.)
Study: NCT02568306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0165-1562
Description: Administered subcutaneously (s.c., under the skin) single dose \[SD\] or multiple dose \[MD\] with daily dosing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) single dose \[SD\]) or multiple dose \[MD\] with daily dosing.
Study: NCT02208843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib tablet once daily until progression
Study: NCT02587052

Intervention type: DRUG
Intervention: Generic tacrolimus
Description: Generic tacrolimus

Intervention type: DRUG
Intervention: Prograf
Description: Prograf, the original tacrolimus
Study: NCT01722409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane and 0.5 μg/kg dexmedetomidine
Description: After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane and 1 μg/kg dexmedetomidine
Description: After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
Study: NCT02980588

Intervention type: DEVICE
Group type: OTHER
Intervention: SGC directed glycemic control
Description: the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC
Study: NCT03328637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT) consisting of weekly 12 sessions will focus on moderated and controlled use of smartphone instead of abstinence model.
Study: NCT02481856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01593644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adenosine + dipyridamole
Description: adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
Study: NCT01388413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly Oral Cyclic Antibiotic programme
Description: The Weekly Oral Cyclic Antibiotic Programme consisted of the alternate administration of an antibiotic once per week. The antibiotics that were chosen (efficient for urinary tract infection, well tolerated, low selection pressure) included : Amoxicillin 6000 mg, Amoxicillin/clavulanic acid 3000 mg, Cefixime 400 mg, Fosfomycin trometamol 6000 mg, Trimethoprim/sulfamethoxazole 2400 mg. During week A,the patient received a single antibiotic (A), and the following week B the patient was given another antibiotic (B). For each patient, antibiotics were specifically chosen according to the results of urine cultures.